4th Annual Gene Therapy for Ophthalmic Disorders Summit

The 4th Annual Gene Therapy for Ophthalmic Disorders Summit is the industry-leading, industry-focused forum for learning how to validate novel administration routes to the eye, extrapolate effectively from preclinical models to inform safety and efficacy and define relevant endpoints for clinical trials.

Across 3 days of in-depth case studies, new data, and focused group discussions, hear from and engage with the likes of Janssen, Adverum Biotechnologies, Spark Therapeutics, SparingVision, AbbVie, and the RD Fund. As well as leveraging insights from these talks and panels: participate in breakout discussions, utilize Q and A time built into talks, and meet and learn from ophthalmic gene therapy leaders during our 5+ hours of dedicated networking time.

This Summit Will Bring Together Leading Voices on:

- Defining Relevant and Meaningful Endpoints
Investigate the latest trends in endpoint development and regulation, understand their applicability in animal model studies to clinical trials, and discuss the need for validated novel endpoints, with key insights from Adverum Biotechnologies and SparingVision.

- Levelling up the Translatability of Preclinical Models
Address the best practices in animal model selection and development, optimize the clinical relevancy of animal model studies, and leverage the latest retinal organoid developments, with expert sessions hosted by Atsena Therapeutics and MeiraGTx.

- Exploring Different Delivery Methods to the Front and Back of the Eye
Take a deep dive into the suprachoroidal route, overcome the AAV cargo capacity challenge with novel administration methods, and hear the latest updated on robotics-assisted subretinal delivery, with exciting discussions from Clearside Biomedical and Splice Bio.

- Understanding the Immune and Inflammatory Responses to Ocular Gene Therapies
How can improved promoters and enhancers deliver genes effectively without triggering the immune response? Which preclinical models are best suited to test the various variables associated with GTAU? What are the latest trends in immunosuppressant regimens being used in the field? Let AGTC and Kriya Therapeutics answer these questions, and many more.

- Leveraging Insights from Ophthalmology-Focused Venture Capital
Discover the current investment landscape for gene therapy in the ophthalmology field, and understand what venture capital investors are looking for when it comes to developing preclinical, clinical, and manufacturing packages in the most fruitful, cost-effective manner, with key insights from the RD Fund and Syncona.

Find out more in our event guide - https://ter.li/65eeyd

Speakers: Glenn Yiu, University of Calfornia Davis, Adam Turpcu, Adverum Biotechnologies, Daniel Chao, Janssen, Sarah Tuller, Opus Genetics, Sheila Nirenberg, Bionic Sight, Samarendra Mohanty, Nanoscope Therapeutics, Catherine Tsilfidis, Ottawa Hospital Research Institute, Adnan Dibas, Nanoscope Technologies, Jasmina Kapetanovic, University of Oxford, Constance Cepko, Harvard University, Melissa Calton, 4D Molecular Therapeutics, Ben Sajdak, Fauna Bio, Eva Andres-Mateos, Atsena Therapeutics, Arun Upadhyay, Ocugen, Jim Wang, Opus Genetics, Snehal Naik, Spark Therapeutics, Jed Chatterton, Spark Therapeutics, Tassos Georgiadis, MeiraGTx, Laura Moreno Leon, Iveric Bio, Simon Petersen-Jones, Michigan State University, Jie Shen, Abbvie, Todd Durham, Foundation Fighting Blindness, Karen Wagner, Ysios Capital Partners, Alicia Kemble, RD Fund, Christine Kay, Atsena Therapeutics, Viral Kansara, Clearside Biomedical, Gaurav Sahay, Oregon State University, Gerard Caelles, Splice Bio, Daniel Chung, SparingVision, Ash Jayagopal, Opus Genetics